Drugs / MK-4884
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07600749 | Jun 2026 → Oct 2029 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4884 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07600749 ↗ |
| Route | Oral | “Oral Administration” NCT07600749 ↗ |